Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 4, 2014, Pages 327-334.e8

  Quintás Cardama, Alfonso ^a   Choi, Sangbum ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a   Huang, Xuelin ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR ABL1; CML; Conditional survival; Nomogram; Prognosis

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

AGE; ARTICLE; CALCULATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONDITIONAL SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; NOMOGRAM; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904621638     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.01.003     Document Type: Article

References (18)

1. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 2.2012. © 2012 National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www. nccn.org/professionals/physician-gls/pdf/cml.pdf. Accessed December 1, 2011.
2. M. Baccarani, J. Cortes, and F. Pane et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
3. B.J. Druker, F. Guilhot, and S.G. O'Brien et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
4. T.P. Hughes, A. Hochhaus, and S. Branford et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765
5. D.E. Henson, and L.A. Ries On the estimation of survival Semin Surg Oncol 10 1994 2 6
6. H. Kantarjian, N.P. Shah, and A. Hochhaus et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
7. N. Shah, H. Kantarjian, and D.W. Kim et al. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib J Clin Oncol 30 2012 (abstract 6506)
8. H. Skuladottir, and J.H. Olsen Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark J Clin Oncol 21 2003 3035 3040
9. D. Rizopoulos An R package for the joint modelling of longitudinal and time-to-event data J Stat Softw 35 2010 1 33
10. A. Tsiatis, and M. Davidian Joint modeling of longitudinal and time-to-event data: an overview Stat Sin 14 2004 809 834
11. G.J. Chang, C.Y. Hu, C. Eng, J.M. Skibber, and M.A. Rodriguez-Bigas Practical application of a calculator for conditional survival in colon cancer J Clin Oncol 27 2009 5938 5943
12. B.A. Zamboni, G. Yothers, and M. Choi et al. Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07 J Clin Oncol 28 2010 2544 2548
13. P.D. Baade, D.R. Youlden, and S.K. Chambers When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects Med J Aust 194 2011 73 77
14. L.F. Ellison, H. Bryant, G. Lockwood, and L. Shack Conditional survival analyses across cancer sites Health Rep 22 2011 21 25
15. X.Q. Yu, P.D. Baade, and D.L. O'Connell Conditional survival of cancer patients: an Australian perspective BMC Cancer 12 2012 460
16. A.M. Vanderwalde, C.L. Sun, and L. Laddaran et al. Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies Leukemia 27 2013 1139 1145
17. P. Jain, H. Kantarjian, and A. Nazha et al. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities Blood 121 2013 4867 4874
18. G. Saglio, D.W. Kim, and S. Issaragrisil et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259